Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study

Int J Cancer. 2004 Jan 10;108(2):277-80. doi: 10.1002/ijc.11519.

Abstract

The lignan enterolactone produced by the intestinal microflora from dietary precursors has been hypothesized to protect against hormone-dependent cancers. We conducted a nested case-control study to examine the relationship between serum enterolactone concentration and risk of breast cancer. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum collected at 4 independent cross-sectional population surveys from 206 women with breast cancer diagnosed during follow-up (mean 8.0 years) and from 215 controls frequency-matched to cases by study cohort, 5-year age group and study area. Mean serum enterolactone concentration (nmol/l) did not significantly differ between case and control subjects [25.2 (SD 22.2) vs. 24.0 (SD 21.3), respectively]. Odds ratios for breast cancer risk estimated by conditional logistic regression for increasing concentration of enterolactone in quartiles were 1.00 (referent), 1.67 (95% CI 0.95-2.95), 1.71 (95% CI 0.96-3.06) and 1.30 (95% CI 0.73-2.31), and p for trend was 0.48. Our findings do not support the hypothesis that high serum enterolactone concentration is associated with reduced risk of breast cancer.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / blood*
  • Adult
  • Aged
  • Breast Neoplasms / blood
  • Breast Neoplasms / epidemiology*
  • Breast Neoplasms / pathology
  • Case-Control Studies
  • Cross-Sectional Studies
  • Estrogens / blood
  • Female
  • Finland / epidemiology
  • Fluoroimmunoassay
  • Humans
  • Lignans / blood*
  • Middle Aged
  • Odds Ratio
  • Postmenopause
  • Premenopause
  • Prospective Studies
  • Risk Factors

Substances

  • Estrogens
  • Lignans
  • 4-Butyrolactone
  • 2,3-bis(3'-hydroxybenzyl)butyrolactone